title: Requirements for baculoviruses for clinical gene therapy applications.
abstract: Baculoviruses have proven capacity for the production of recombinant proteins including virus-like particles and as viral vectors. Recent progress in preclinical studies suggest that baculoviruses have potential as new vectors for gene therapy but so far no clinical trials have been performed. To date, no specific guidelines for the use of baculoviruses as human gene therapy vectors exist but researchers can utilize existing guidelines made for other biological products. Because of the long history of research on baculoviruses, a lot of knowledge has been obtained that forms a good basis for the gene therapy development process. This article gives an overview of the current status of the application of baculovirus vectors in gene therapy and summarizes some of the challenges to overcome before the first clinical trials with baculoviruses can be accomplished.
authors.affiliation: AI Virtanen Institute Department of Biotechnology and Molecular Medicine, University of Eastern Finland/Kuopio, Finland.
authors.forename: Hanna P
authors.initials: HP
authors.lastname: Lesch
authors.forename: Kaisa-Emilia
authors.initials: KE
authors.lastname: Makkonen
authors.forename: Anna
authors.initials: A
authors.lastname: Laitinen
authors.forename: Ann-Marie
authors.initials: AM
authors.lastname: Määttä
authors.forename: Outi
authors.initials: O
authors.lastname: Närvänen
authors.forename: Kari J
authors.initials: KJ
authors.lastname: Airenne
authors.forename: Seppo
authors.initials: S
authors.lastname: Ylä-Herttuala
mesh_terms: D016367:Baculoviridae / Q000235:genetics*; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods / Q000592:standards*; D005822:Genetic Vectors / Q000592:standards*; D017408:Guidelines as Topic; D006801:Humans; D011786:Quality Control